Uncharacterized Protein, Uncharacterized
Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 11 |
NetGPI | no | yes: 0, no: 11 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005739 | mitochondrion | 5 | 1 |
GO:0043226 | organelle | 2 | 1 |
GO:0043227 | membrane-bounded organelle | 3 | 1 |
GO:0043229 | intracellular organelle | 3 | 1 |
GO:0043231 | intracellular membrane-bounded organelle | 4 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 1 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pescher et al. (upgregulation) | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Lahav et al. - mRNA
- Protein
|
Related structures:
AlphaFold database: A4IDT5
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 196 | 200 | PF00656 | 0.328 |
CLV_C14_Caspase3-7 | 272 | 276 | PF00656 | 0.409 |
CLV_MEL_PAP_1 | 133 | 139 | PF00089 | 0.306 |
CLV_NRD_NRD_1 | 207 | 209 | PF00675 | 0.460 |
CLV_PCSK_KEX2_1 | 152 | 154 | PF00082 | 0.525 |
CLV_PCSK_KEX2_1 | 206 | 208 | PF00082 | 0.487 |
CLV_PCSK_PC1ET2_1 | 152 | 154 | PF00082 | 0.525 |
CLV_PCSK_SKI1_1 | 157 | 161 | PF00082 | 0.441 |
CLV_PCSK_SKI1_1 | 222 | 226 | PF00082 | 0.447 |
DEG_APCC_DBOX_1 | 77 | 85 | PF00400 | 0.453 |
DOC_MAPK_MEF2A_6 | 183 | 192 | PF00069 | 0.408 |
DOC_PP4_FxxP_1 | 45 | 48 | PF00568 | 0.345 |
DOC_USP7_MATH_1 | 102 | 106 | PF00917 | 0.333 |
DOC_USP7_MATH_1 | 143 | 147 | PF00917 | 0.341 |
DOC_USP7_MATH_1 | 151 | 155 | PF00917 | 0.316 |
DOC_USP7_MATH_1 | 227 | 231 | PF00917 | 0.489 |
DOC_USP7_MATH_1 | 255 | 259 | PF00917 | 0.463 |
DOC_USP7_MATH_1 | 73 | 77 | PF00917 | 0.456 |
DOC_USP7_UBL2_3 | 107 | 111 | PF12436 | 0.470 |
DOC_WW_Pin1_4 | 119 | 124 | PF00397 | 0.505 |
DOC_WW_Pin1_4 | 214 | 219 | PF00397 | 0.367 |
DOC_WW_Pin1_4 | 44 | 49 | PF00397 | 0.505 |
LIG_14-3-3_CanoR_1 | 136 | 142 | PF00244 | 0.343 |
LIG_14-3-3_CanoR_1 | 183 | 189 | PF00244 | 0.420 |
LIG_14-3-3_CanoR_1 | 240 | 248 | PF00244 | 0.463 |
LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.397 |
LIG_BIR_III_4 | 23 | 27 | PF00653 | 0.302 |
LIG_BRCT_BRCA1_1 | 70 | 74 | PF00533 | 0.479 |
LIG_FHA_1 | 132 | 138 | PF00498 | 0.363 |
LIG_FHA_2 | 194 | 200 | PF00498 | 0.493 |
LIG_FHA_2 | 270 | 276 | PF00498 | 0.400 |
LIG_FHA_2 | 91 | 97 | PF00498 | 0.493 |
LIG_HCF-1_HBM_1 | 139 | 142 | PF13415 | 0.263 |
LIG_LIR_Apic_2 | 56 | 60 | PF02991 | 0.341 |
LIG_LIR_Gen_1 | 158 | 167 | PF02991 | 0.345 |
LIG_LIR_Gen_1 | 38 | 48 | PF02991 | 0.351 |
LIG_LIR_Gen_1 | 6 | 14 | PF02991 | 0.317 |
LIG_LIR_Nem_3 | 158 | 162 | PF02991 | 0.372 |
LIG_LIR_Nem_3 | 38 | 43 | PF02991 | 0.371 |
LIG_LIR_Nem_3 | 6 | 10 | PF02991 | 0.323 |
LIG_LIR_Nem_3 | 75 | 80 | PF02991 | 0.337 |
LIG_SH2_CRK | 166 | 170 | PF00017 | 0.431 |
LIG_SH2_CRK | 7 | 11 | PF00017 | 0.324 |
LIG_SH2_GRB2like | 7 | 10 | PF00017 | 0.249 |
LIG_SH2_NCK_1 | 57 | 61 | PF00017 | 0.401 |
LIG_SH2_SRC | 197 | 200 | PF00017 | 0.435 |
LIG_SH2_STAP1 | 234 | 238 | PF00017 | 0.507 |
LIG_SH2_STAP1 | 7 | 11 | PF00017 | 0.410 |
LIG_SH2_STAT5 | 17 | 20 | PF00017 | 0.406 |
LIG_SH2_STAT5 | 197 | 200 | PF00017 | 0.340 |
LIG_SH2_STAT5 | 234 | 237 | PF00017 | 0.429 |
LIG_SH2_STAT5 | 7 | 10 | PF00017 | 0.396 |
LIG_SH2_STAT5 | 80 | 83 | PF00017 | 0.442 |
LIG_WW_1 | 4 | 7 | PF00397 | 0.440 |
MOD_CK1_1 | 118 | 124 | PF00069 | 0.369 |
MOD_CK1_1 | 230 | 236 | PF00069 | 0.431 |
MOD_CK1_1 | 61 | 67 | PF00069 | 0.490 |
MOD_CK1_1 | 68 | 74 | PF00069 | 0.452 |
MOD_CK2_1 | 73 | 79 | PF00069 | 0.482 |
MOD_CK2_1 | 90 | 96 | PF00069 | 0.395 |
MOD_GlcNHglycan | 1 | 4 | PF01048 | 0.530 |
MOD_GlcNHglycan | 153 | 156 | PF01048 | 0.361 |
MOD_GlcNHglycan | 257 | 260 | PF01048 | 0.472 |
MOD_GlcNHglycan | 70 | 73 | PF01048 | 0.401 |
MOD_GSK3_1 | 102 | 109 | PF00069 | 0.415 |
MOD_GSK3_1 | 115 | 122 | PF00069 | 0.414 |
MOD_GSK3_1 | 131 | 138 | PF00069 | 0.247 |
MOD_GSK3_1 | 230 | 237 | PF00069 | 0.384 |
MOD_GSK3_1 | 246 | 253 | PF00069 | 0.253 |
MOD_GSK3_1 | 58 | 65 | PF00069 | 0.355 |
MOD_GSK3_1 | 68 | 75 | PF00069 | 0.318 |
MOD_N-GLC_1 | 115 | 120 | PF02516 | 0.436 |
MOD_N-GLC_1 | 131 | 136 | PF02516 | 0.334 |
MOD_N-GLC_1 | 227 | 232 | PF02516 | 0.439 |
MOD_N-GLC_1 | 240 | 245 | PF02516 | 0.343 |
MOD_N-GLC_1 | 90 | 95 | PF02516 | 0.362 |
MOD_NEK2_1 | 115 | 120 | PF00069 | 0.388 |
MOD_NEK2_1 | 248 | 253 | PF00069 | 0.367 |
MOD_NEK2_1 | 269 | 274 | PF00069 | 0.463 |
MOD_NEK2_2 | 102 | 107 | PF00069 | 0.457 |
MOD_NEK2_2 | 178 | 183 | PF00069 | 0.452 |
MOD_NEK2_2 | 62 | 67 | PF00069 | 0.469 |
MOD_OFUCOSY | 113 | 119 | PF10250 | 0.240 |
MOD_PKA_2 | 135 | 141 | PF00069 | 0.346 |
MOD_Plk_1 | 157 | 163 | PF00069 | 0.354 |
MOD_Plk_4 | 193 | 199 | PF00069 | 0.472 |
MOD_Plk_4 | 80 | 86 | PF00069 | 0.386 |
MOD_ProDKin_1 | 119 | 125 | PF00069 | 0.511 |
MOD_ProDKin_1 | 214 | 220 | PF00069 | 0.370 |
MOD_ProDKin_1 | 44 | 50 | PF00069 | 0.500 |
MOD_SUMO_rev_2 | 146 | 154 | PF00179 | 0.476 |
TRG_DiLeu_BaEn_2 | 204 | 210 | PF01217 | 0.408 |
TRG_ENDOCYTIC_2 | 7 | 10 | PF00928 | 0.412 |
TRG_ER_diArg_1 | 206 | 208 | PF00400 | 0.315 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N0P495 | Leptomonas seymouri | 61% | 100% |
A0A0S4JKK5 | Bodo saltans | 24% | 98% |
A0A1X0P327 | Trypanosomatidae | 35% | 96% |
A0A3Q8IPM4 | Leishmania donovani | 99% | 100% |
A0A422NMF9 | Trypanosoma rangeli | 35% | 100% |
A4HQ29 | Leishmania braziliensis | 77% | 100% |
D0A8T8 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 33% | 100% |
E9ATU7 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 86% | 100% |
Q4Q0P9 | Leishmania major | 90% | 100% |
V5BWK1 | Trypanosoma cruzi | 35% | 100% |